Skip to main content
Terug
Watch Compare

Ocean Biomedical, Inc.

Datakwaliteit: 83%
OCEA
OTC Manufacturing Chemicals
€ 0,00
€ 0,00 (0,00%)
Marktkapitalisatie: 69.709,0
Prijs
€ 0,00
Marktkapitalisatie
69.709,0
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -4,05 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio0,06
Interest Coverage-2,42

Waardering

PE (TTM)
0,00
Boven sectorgemiddelde (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E 0,0 -1,5
P/B — 1,6
ROE % — -54,0
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Geen toekomstige schattingen beschikbaar

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q32023 N/A -€ 0,52 —
Q22023 -€ 0,20 -€ 0,41 -112,6%
Q12023 -€ 0,17 -€ 0,27 -60,6%
Q42022 -€ 0,16 N/A —

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -30,72 M
ROE N/A ROA -2263,74%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -4,05 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,06
Interest Coverage -2,42 Asset Turnover N/A
Working Capital -25,08 M Tangible Book Value -92,40 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 0,00 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -5811,30%
Market Cap 69.709,0 Enterprise Value 69.709,0
Per Share
EPS (Diluted TTM) -0,91 Revenue / Share N/A
FCF / Share -0,02 OCF / Share -0,02
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 13,19%
SBC-Adj. FCF -4,24 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2021 FY2022
Revenue — — — —
Net Income -9,48 M -114,47 M -564.110,0 -958.430,0
EPS (Diluted) -0,34 -4,35 — —
Gross Profit — — — —
Operating Income -3,80 M -10,21 M -566.558,0 -2,48 M
EBITDA — — — —
R&D Expenses 26.000,0 709.000,0 — —
SG&A Expenses — — — —
D&A — — — —
Interest Expense -2,05 M 50.000,0 — 691,0
Income Tax — — — —

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2021 FY2022
Total Assets 902.000,0 5,50 M 108,65 M 110,91 M
Total Liabilities 98,52 M 96,26 M 3,40 M 6,61 M
Shareholders' Equity -97,62 M -90,76 M -1,84 M -6,15 M
Total Debt 3,20 M 3,20 M — —
Cash & Equivalents — — 0,0 —
Current Assets 812.000,0 2,11 M 1,55 M 467.989,0
Current Liabilities 33,89 M 30,01 M 246.444,0 3,46 M